Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic...

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Cancer cachexia is a significant cause of mortality in advanced cancer patients.
• Effective pharmacological treatments for cancer cachexia remain limited.
• Systemic hyperinflammation often accompanies cancer cachexia.

Purpose of the Study:

• To evaluate the efficacy of tocilizumab in treating cancer cachexia with systemic hyperinflammation.
• To assess the safety profile of tocilizumab in this patient population.
• To compare tocilizumab plus corticosteroids against corticosteroids alone.

Main Methods:

• A single-center retrospective study involving 20 patients treated with tocilizumab and 20 matched controls.
• Both groups received corticosteroids; the treatment group received an additional dose of tocilizumab (8 mg/kg).
• Key efficacy and safety parameters were recorded, including weight, BMI, ECOG score, handgrip strength, and inflammatory markers.

Main Results:

• Tocilizumab treatment significantly improved patient biomarkers and ameliorated systemic inflammation (p<0.05).
• Enhanced short-term efficacy was observed, including symptomatic relief (60% vs. 20%), improved albumin/prealbumin (70% vs. 25%), and weight gain (45% vs. 15%).
• Tocilizumab was safe, with no increased infection or ICU admission rates, and facilitated restarting antitumor therapy (70% vs. 35%).

Conclusions:

• Tocilizumab combined with corticosteroids is effective in alleviating cancer cachexia and systemic hyperinflammation.
• This combination demonstrates favorable short-term clinical efficacy and safety.
• The tocilizumab-corticosteroid regimen shows potential as a novel treatment strategy for cancer cachexia.